Currently, clinical studies of hepcidin agonists primarily center around the use of direct hepcidin formulations, although their uses are currently limited to iron overload induced by hereditary hemochromatosis and beta-thalassemia [153]. Here, HAMP is linked to hereditary hemochromatosis.